Adam B. Keeton

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

Targeting phosphodiesterase 10A disrupts MAPK signaling pathways in the tumor microenvironment to unleash antitumor immunity

This study shows that PDE10A inhibition with ADT-030 suppresses tumor growth by disrupting MAPK signaling and enhancing antitumor immunity through immune cell modulation.

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

This study evaluates the potency and selectivity of the pan-RAS inhibitor ADT-007 in 3D bioprinted organoid tumor models of KRAS-mutant and RAS wild-type colorectal cancer.